Answers are grounded in this paper and cite their sources.
Peroxisome proliferator-activated receptor (PPAR) is a family of nuclear receptor transcription factors that regulates immune cell growth, differentiation and homeostasis. We and others have shown earlier that in vivo treatment with PPAR , / or agonists ameliorates experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS). In this study we show that C57BL/6 mice induced to develop EAE display augmented neural antigen-specific T cell response that was inhibited by PPAR agonist 15-deoxy-12,14 -Prostaglandin J 2 (15d-PGJ 2 ). EAE mice showed elevated expression of IFN and IL-17 in the CNS and lymphoid organs compared to nave mice that decreased significantly following treatment with 15d-PGJ 2 . EAE mice also expressed elevated levels of IL-12 and IL-23 that decreased after treatment with 15d-PGJ 2 . 15d-PGJ2 also attenuated the expression of IFN , IL-17, IL-12 and IL-23 in neural antigenspecific spleen cells ex vivo and in vitro. Moreover, EAE mice expressed low levels of IL-4, IL-10 and PPAR compared to nave that increased significantly following treatment with 15d-PGJ2. However, 15d-PGJ2 failed to change the expansion of CD4 + CD25 + Foxp3 + Treg cells in EAE. These findings suggest that 15d-PGJ2 differentially regulates CD4 + T helper cell subset responses in EAE.
No takes yet. Share an insight, caveat, or question.
Saravanan Kanakasabai (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: